Blue Dream #8
A numbered phenotype cut of Blue Dream with limited verifiable provenance and no chemistry meaningfully distinct from its parent.
Growing, buying or possessing cannabis and seeds is legal only in some places. Check the law where you live before acting on this information.
Blue Dream #8 is best understood as a pheno-hunted selection of Blue Dream sold by various nurseries and seedbanks. There is no authoritative registry that defines what 'pheno #8' means — different vendors number their cuts differently. Assume its effects and chemistry sit inside the normal Blue Dream range: myrcene- or pinene-forward, THC-dominant, sativa-leaning in reported effect. Anyone promising you a specific, reproducible experience from a numbered pheno without lab data is selling a story, not a strain.
Overview
Blue Dream #8 is one of several numbered selections circulating under the Blue Dream name. 'Pheno numbers' are internal labels breeders use during pheno-hunting — the process of germinating many seeds from the same cross and picking standout individuals. Numbers are not standardized across breeders, so 'Blue Dream #8' from one seed company has no guaranteed relationship to '#8' from another Strong evidence.
The parent strain, Blue Dream, is widely reported to be a cross of Blueberry and Haze and became one of the best-selling cultivars in legal U.S. markets in the 2010s [1][2]. Blue Dream #8 inherits that commercial context: the name sells, the specifics rarely check out.
Chemistry
There is no peer-reviewed chemotyping study specific to a cut labeled 'Blue Dream #8.' What we can say comes from aggregated lab data on Blue Dream samples generally.
Cannabinoids. Blue Dream samples in U.S. testing databases typically fall in the 17–24% THC range with negligible CBD (<1%) [3] Weak / limited. CBG and minor cannabinoids sit at low single-digit percentages at most.
Terpenes. Chemotype work on Blue Dream and related 'Haze' descendants shows terpene profiles are variable but commonly myrcene-dominant, sometimes with elevated α-pinene, β-caryophyllene, and terpinolene [4] Weak / limited. The old marketing claim that 'myrcene above 0.5% makes a strain indica' is folklore with no controlled human evidence behind it [5] Disputed.
Because phenotype selections drift over time through cloning and re-selection, chemistry from a specific '#8' cut can only be trusted when it comes with a batch-specific certificate of analysis.
Reported effects
No clinical trial has ever tested Blue Dream, let alone a numbered phenotype of it. Effect descriptions come from user reports on commercial menus and review sites, which are subject to placebo, expectancy, and marketing effects [6] Anecdote.
Commonly reported effects for the Blue Dream family:
- Euphoric, talkative onset
- Mild body relaxation without heavy sedation
- Dry mouth and dry eyes (typical of most THC-dominant flower)
There is no reliable evidence that a #8 phenotype produces effects distinguishable from other Blue Dream cuts in a blinded setting. The industry-standard claim that indica vs. sativa vs. hybrid labels predict effects is not supported by chemotyping research [7] Strong evidence.
Lineage (disputed)
Blue Dream's lineage is popularly listed as Blueberry × Haze, with the original selection often credited to Santa Cruz growers in the mid-2000s. The specific Blueberry and Haze cuts used, and the identity of the original breeder, are not conclusively documented in any primary source [1] Disputed.
For Blue Dream #8 specifically:
- No breeder has published a verifiable origin story with dates, seed lot numbers, or genetic testing tying '#8' to a defined mother plant.
- Multiple seedbanks and clone-only vendors sell 'Blue Dream #8' independently of each other.
- Without genotyping (e.g., via services like Phylos or Medicinal Genomics), there is no way to confirm two '#8' cuts are the same plant [8] Weak / limited.
Treat any lineage chart for this strain as marketing until a verifiable genetic report is attached.
Cultivation basics
Grower reports for Blue Dream selections, including numbered phenos, are broadly consistent Anecdote:
- Flowering time: ~63–70 days indoors.
- Structure: Tall, stretchy, Haze-influenced. Responds well to topping, LST, and SCROG to manage canopy.
- Yield: Moderate to high indoors; vigorous outdoors in Mediterranean-type climates.
- Common issues: Susceptible to powdery mildew in humid environments; watch VPD during late flower.
- Nutrients: Handles standard feeding schedules; not notably heavy or light feeding compared to other hybrids.
None of this is unique to '#8.' If you're buying seeds or clones, ask the vendor for a batch COA and, ideally, a genotype report before assuming you're getting anything specific.
Marketing vs. reality
What the name promises: a special, elite cut of Blue Dream with distinctive effects.
What the evidence supports:
- Blue Dream is a real, widely-grown cultivar family with meaningful commercial history [2].
- 'Phenotype numbers' are internal breeder shorthand, not a standardized designation Strong evidence.
- No published chemotyping or clinical data distinguishes '#8' from other Blue Dream cuts No data.
- Effect predictions from strain names generally do not survive blinded testing [7] Strong evidence.
If a #8 cut you tried felt great, that's a legitimate personal data point. It's not evidence the number on the tag caused the experience.
Sources
- Reported Halperin, A. (2019). 'How Blue Dream, the pot strain that fueled the legal weed industry, lost its buzz.' The Washington Post.
- Reported Leafly Staff. Blue Dream strain data and market share reporting. Leafly.
- Peer-reviewed Jikomes, N., & Zoorob, M. (2018). The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. Scientific Reports, 8, 4519.
- Peer-reviewed Smith, C. J., Vergara, D., Keegan, B., & Jikomes, N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLoS ONE, 17(5), e0267498.
- Peer-reviewed Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1), 44–46.
- Peer-reviewed Gilman, J. M., et al. (2022). Effect of medical marijuana card ownership on pain, insomnia, and affective disorder symptoms in adults: A randomized clinical trial. JAMA Network Open, 5(3), e222106.
- Peer-reviewed Watts, S., McElroy, M., Migicovsky, Z., Maassen, H., van Velzen, R., & Myles, S. (2021). Cannabis labelling is associated with genetic variation in terpene synthase genes. Nature Plants, 7, 1330–1334.
- Peer-reviewed Sawler, J., Stout, J. M., Gardner, K. M., Hudson, D., Vidmar, J., Butler, L., Page, J. E., & Myles, S. (2015). The genetic structure of marijuana and hemp. PLoS ONE, 10(8), e0133292.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Blue Dream — A widely-cloned hybrid with strong yields, disputed origins, and no strain-specific clinic...
- Haze — A 1970s Californian sativa that became modern cannabis's most influential breeding line.